Genoproteomic mining of urothelial cancer suggests γ-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy

American Journal of Pathology

Volumn 175, Issue 5, 2009, Pages 1824-1830

  Pollard, Courtney ^a   Nitz, Matt ^a   Baras, Alex ^b   Williams, Paul ^a   Moskaluk, Christopher ^b   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; CISPLATIN; DIAZEPAM BINDING INHIBITOR; DOXORUBICIN; GAMMA GLUTAMYL HYDROLASE; MESSENGER RNA; METHOTREXATE; SURVIVIN; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FUNCTIONAL PROTEOMICS; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; UPREGULATION;

EID: 73649138882     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090155     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics. 2008. CA Cancer J Clin 2008, 58:71-96
2. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866
3. Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhøi BP, Sengeløv L, Jensen KME, Ørntoft TF: Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007, 13:4407-4414
4. Guirguis R, Javadpour N, Sharareh S, Biswas C, el-Amin W, Mansur I, Kim JS: A new method for evaluation of urinary autocrine motility factor and tumor cell collagenase stimulating factor as markers for urinary tract cancers. J Occup Med 1990, 32:846-853
5. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC: Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001, 285:324-328
6. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y: Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005, 11:2625-2636
7. Takata R, Katagiri T, Kanehira M, Shuin T, Miki T, Namiki M, Kohri K, Tsunoda T, Fujioka T, Nakamura Y: Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci 2007, 98:113-117
8. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M: The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006, 7:R80
9. Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D: Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004, 64:7813-7821
10. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C: ONCOMINE: defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006, 24:778-789
11. Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K, Ørntoft TF: ONCOMINE: Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004, 64:4040-4048
12. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Edgar R: NCBI GEO: mining tens of millions of expression profiles - database and tools update. Nucleic Acids Res 2007, 35:D760-765
13. Dyrskjøt L, Kruhøffer M, Thykjaer T, Marcussen N, Jensen JL, Møller K, Ørntoft TF: Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004, 64:4040-4048
14. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002, 30:207-210
15. Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193
16. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP: Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:e15
17. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264
18. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537
19. Cheng Q, Cheng C, Crews KR, Ribeiro RC, Pui C-H, Relling MV, Evans WE: Epigenetic regulation of human γ-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am J Hum Genet 2006, 79:264-274
20. Cole PD, Kamen BA, Gorlick R, Banerjee D, Smith AK, Magill E, Bertino JR: Effects of overexpression of γ-glutamyl hydrolase on methotrexate metabolism and resistance. Cancer Res 2001, 61:4599-4604
21. Longo GS, Gorlick R, Tong WP, Lin S, Steinherz P, Bertino JR: γ-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res 1997, 9:259-263
22. Waltham MC, Li W-W, Gritsman H, Tong WP, Bertino JR: γ-Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists. Mol Pharmacol 1997, 51:825-832
23. Whitehead VM, Kalman TI: Enhanced accumulation of long-chain methotrexate polyglutamates in human T cell acute lymphoblastic leukemia cell lines by avicin. Proc Am Soc Hematol 1997, 80:327a
24. Harrington DP, Fleming T: A class of rank test procedures for censored survival data. Biometrika 1982, 69:553-566
25. Julious SA: Two-sided confidence intervals for the single proportion: comparison of seven methods by Robert G. Newcombe, Statistics in Medicine 1998; 17:857-872. Stat Med 2005, 24:3383-3384
26. Wilson EB: Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927, 22:209-212
27. Galivan J, Ryan TJ, Chave K, Rhee M, Yao R, Yin D: Glutamyl hydrolase: pharmacological role and enzymatic characterization. Pharmacol Ther 2000, 85:207-215
28. Mcguire JJ, Coward JK: Pteroylpolyglutamates: biosynthesis, degradation, and function. Folates and Pterins. Edited by Blakley RL, Benkovic SJ. New York, Wiley, 1984, pp 135-190
29. Silink M, Reddel R, Bethel M, Rowe PB: γ-Glutamyl hydrolase (conjugase): purification and properties of the bovine hepatic enzyme. J Biol Chem 1975, 250:5982-5994
30. O'Connor BM, Rotundo RF, Nimec Z, McGuire JJ, Galivan J: Secretion of γ-glutamyl hydrolase in vitro. Cancer Res 1991, 51:3874-3881
31. He P, Varticovski L, Bowman ED, Fukuoka J, Welsh JA, Miura K, Jen J, Gabrielson E, Brambilla E, Travis WD, Harris CC: Identification of carboxypeptidase E and γ-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol 2004, 35:1196-1209
32. Guidotti A, Forchetti CM, Corda MG, Konkel D, Bennett CD, Costa E: Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci USA 1983, 80:3531-3535
33. Anholt RR, Pedersen PL, De Souza EB, Snyder SH: The peripheraltype benzodiazepine receptor: localization to the mitochondrial outer membrane. J Biol Chem 1986, 261:576-583
34. Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ, Trump DL, Natale RB, Grossman HB, Crawford ED: Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 2009, 115:4104-4109